What is the clinical significance of mitochondrial DNA variants and heteroplasmy distribution across tissues?

• A. Heteroplasmy level determines disease severity; tissue distribution explains variable presentations; maternal inheritance.
• B. Nuclear DNA variants alone determine mitochondrial disease severity; paternal inheritance dominates.
• C. Mitochondrial DNA inheritance is strictly paternal.
• D. Heteroplasmy levels do not affect phenotype.

Answer: (A)

The key idea is that mitochondrial disease is driven by the amount and distribution of mutant mitochondrial DNA across tissues. The proportion of mutant mtDNA in a cell, known as heteroplasmy, determines whether energy production is compromised enough to cause symptoms—the higher the heteroplasmy, the more likely organs with high energy demands (like brain, muscle, heart) will be affected, leading to variable and tissue-specific presentations. Because mtDNA is inherited almost exclusively from the mother, all children of an affected mother can inherit the mutation, but the severity in each child varies due to different heteroplasmy levels established during oogenesis and the subsequent distribution of mutant mtDNA in different tissues. This also explains why blood heteroplasmy might not mirror the burden in affected tissues, so testing more relevant tissues (such as muscle) can be informative. Statements that rely only on nuclear DNA, insist paternal inheritance dominates, or claim heteroplasmy doesn’t influence phenotype don’t fit the observed patterns of mitochondrial disease.